NMNombulelo Magula

Nombulelo Magula

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nombulelo Magula has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Corrigendum: Unlocking insights into HIV care: An in-depth analysis of key populations from the Fast-Track Cities Quality of Care survey in eThekwini, KwaZulu-Natal, South Africa

    by Somasundram Pillay, Nombulelo Magula, Nceba Gqaleni, Deepak Singh, José M. Zúñiga

    The Southern African Journal of HIV Medicine is focused on HIV/AIDS treatment, prevention and related topics relevant to clinical and public health practice. The purpose of the journal is to disseminate original research results and support high-level learning related to HIV Medicine. It publishes original research articles, editorials, case reports/case series, reviews of state-of-the-art clinical practice and correspondence.

  • Open Access

    Unlocking insights into HIV care: An in-depth analysis of key populations from the Fast-Track Cities Quality of Care survey in eThekwini, KwaZulu-Natal, South Africa

    by Somasundram Pillay, Nombulelo Magula, Nceba Gqaleni, Deepak Singh, Zuniga M. Jose

    Background: Key populations experience disproportionate HIV burdens and structural barriers to care. Objective: To compare healthcare utilisation, HIV knowledge and barriers between key population groups (KPG) and non-key populations living with HIV in eThekwini, South Africa. Methods: We analysed the eThekwini Fast-Track Cities Quality of Care survey, a cross-sectional study across 30 high-HIV-burden facilities (April to July 2023). Adults living with HIV completed anonymous questionnaires; groups were compared using χ2 tests and multivariable logistic regression for partner notification. Results: Of 517 analysed participants, 128 (24.8%) were KPG. KPG participants were younger, more recently diagnosed (< 1 year: 9.4% vs 1.3%) and more often on antiretroviral therapy (ART) for 1–4 years (52.3% vs 33.4%), with similar daily adherence (~83%). KPG were more likely to access care via non-governmental organisations (NGOs; 23.4% vs 5.7%). Controls more often understood undetectable viral load (36.0% vs 21.9%) and that treatment benefits outweigh side effects (65.3% vs 42.9%). KPG more frequently reported undetectable viral load (55.5% vs 29.8%), more frequent screening for co-morbid conditions, and transport-cost barriers (15.6% vs 8.2%). In KPG, NGO care was associated with partner notification (adjusted odds ratio 18.06; 95% confidence interval 4.77–68.41). Conclusion: There are marked differences between KPG and adults with HIV in healthcare utilisation, HIV knowledge and structural barriers.

  • Open Access

    Clearance of persistent SARS-CoV-2 associates with increased neutralizing antibodies in advanced HIV disease post-ART initiation

    by Farina Karim, Catherine Riou, Mallory Bernstein, Zesuliwe Jule, Gila Lustig, Strauss van Graan, Roanne S. Keeton, Janine-Lee Upton, Yashica Ganga, Khadija Khan, et al.

    SARS-CoV-2 clearance requires adaptive immunity but the contribution of neutralizing antibodies and T cells in different immune states is unclear. Here we ask which adaptive immune responses associate with clearance of long-term SARS-CoV-2 infection in HIV-mediated immunosuppression after suppressive antiretroviral therapy (ART) initiation. We assembled a cohort of SARS-CoV-2 infected people in South Africa (n = 994) including participants with advanced HIV disease characterized by immunosuppression due to T cell depletion. Fifty-four percent of participants with advanced HIV disease had prolonged SARS-CoV-2 infection (>1 month). In the five vaccinated participants with advanced HIV disease tested, SARS-CoV-2 clearance associates with emergence of neutralizing antibodies but not SARS-CoV-2 specific CD8 T cells, while CD4 T cell responses were not determined due to low cell numbers. Further, complete HIV suppression is not required for clearance, although it is necessary for an effective vaccine response. Persistent SARS-CoV-2 infection led to SARS-CoV-2 evolution, including virus with extensive neutralization escape in a Delta variant infected participant. The results provide evidence that neutralizing antibodies are required for SARS-CoV-2 clearance in HIV-mediated immunosuppression recovery, and that suppressive ART is necessary to curtail evolution of co-infecting pathogens to reduce individual health consequences as well as public health risk linked with generation of escape mutants.


  • Open Access

    Assessing index CD4 and associated outcomes at 1-year in a tertiary HIV clinic, KwaZulu-Natal

    by Zanele R. Moya, Somasundram Pillay, Nombulelo Magula

    Background: Human immunodeficiency virus (HIV) management guidelines have evolved from initiating therapy at CD4 counts of ≤ 200 cells/m3 to implementing universal test and treat (UTT). This study aimed to assess whether in clinical practice, patients are presenting with higher baseline CD4 counts, describe the incidence of opportunistic infections and the proportion that achieved viral suppression. Methods: A retrospective cohort design with convenience sampling was conducted. Cohort 1 included patients initiated on antiretroviral therapy (ART) between 01 January 2014 and 31 December 2014, when criteria were set at CD4 count ≤ 350 cells/mm3. Cohort 2 included patients initiated on ART between 01 January 2019 and 31 December 2019, during the UTT era. Results: At ART initiation, the median CD4 cell was 170 cells/mm3 (interquartile range [IQR]: 85.5–287) in Cohort 1 cells/mm3 and 243 cells/mm3 (IQR: 120–411) in Cohort 2. Tuberculosis was the predominant OI in the group with CD4 cell count ≤ 200 cells/m3 in both Cohort 1 (26.8%) and Cohort 2 (27.9%), p = 0.039. At 1 year, virological suppression was achieved in only 77.7% and 84.7% of Cohorts 1 and 2 patients. Conclusion: A notable portion of patients at King Edward VIII Hospital’s HIV clinic commenced ART with CD4 counts significantly below the recommended guideline thresholds. Contribution: The research revealed a delay in initiating ART. A comprehensive reevaluation is essential to pinpoint the factors contributing to this delay and to devise customised interventions.


  • Progressive resistance training irrespective of whey protein intake improves quality of life in HIV-infected individuals on antiretroviral therapy

    by Takshita Sookan, Ayesha A. Motala, Michael J. Ormsbee, Jose Antonio, Nombulelo P. Magula, Umesh G. Lalloo, Andrew J. Mckune

    The study aimed to determine whether a progressive resistance training (PRT) programme and whey protein intake could affect the quality of life (QOL) in HIV-infected individuals receiving antiretroviral therapy (ART). Sixty HIV-infected individuals were ...

  • Open Access

    Treatment outcomes of Gene Xpert positive tuberculosis patients in KwaMashu Community Health Centre, KwaZulu-Natal, South Africa: A retrospective review

    by Sarusha Pillay, Nombulelo P. Magula

    Background: We sought to investigate the relationship between tuberculosis (TB) treatment outcomes and its predictors in the KwaMashu region in KwaZulu-Natal (KZN). This area is currently a hotbed for TB and human immunodeficiency virus (HIV) co-infection. Method: A retrospective study design was adopted to characterise adult patients diagnosed with Gene Expert (GXP) positive pulmonary TB from 01 January 2016 to 31 December 2017. Tuberculosis treatment outcomes were assessed after two months and five months according to the standard World Health Organization (WHO) criteria. Multiple logistic regression analysis was used to calculate the odds ratio (OR) of the possible determinants associated with unsuccessful treatment outcomes. Results: Amongst the 596 patients diagnosed, 57.4% (95% confidence interval [CI]: 53.3–61.4; 342 of 596) had successful treatment outcomes. Of these reported cases, 88.89% (85.1–92.0; 304 of 342) were cured. For the unsuccessful treatment outcomes, 52.4% (46.0–58.6; 133 of 254) patients were lost to follow-up, 20.9% (16.0–26.4; 53 of 254) failed treatment, 1.2% (0.2–3.4; 3 of 254) died and 25.6% (20.3–31.4; 65 of 254) of the patients could not be accounted for. Patients with unknown HIV status were more likely to have unsuccessful treatment outcomes (adjusted OR [aOR] = 4.94 [1.83–13.36]). Patients who had sputum conversion at 2 months (aOR = 1.94 [1.27–2.96]) were significantly more likely to exhibit unsuccessful treatment outcomes. Conclusion: Treatment success rate was 57.4% which was below the target set by the WHO. This underscores the urgent need to strengthen treatment adherence strategies to improve outcomes, especially in high HIV burden settings.


  • Open Access

    A trio of infectious diseases and pulmonary embolism: A developing world’s reality

    by Somasundram Pillay, Nombulelo Magula

    The Southern African Journal of HIV Medicine is focused on HIV/AIDS treatment, prevention and related topics relevant to clinical and public health practice. The purpose of the journal is to disseminate original research results and support high-level learning related to HIV Medicine. It publishes original research articles, editorials, case reports/case series, reviews of state-of-the-art clinical practice and correspondence.


  • Open Access

    Risk factors and co-morbidities associated with changes in renal function among antiretroviral treatment-naïve adults in South Africa: A chart review

    by Shirelle Assaram, Tivani P. Mashamba-Thompson, Nombulelo P. Magula

    Introduction: Our systematic scoping review has demonstrated a research gap in antiretroviral treatment (ART) nephrotoxicity as well as in the long-term outcomes of renal function for patients on ART in South Africa. Bearing in mind the high prevalence of human immunodeficiency virus (HIV) in South Africa, this is of great concern. Objectives: To determine the risk factors and co-morbidities associated with changes in renal function in HIV-infected adults in South Africa. Methods: We conducted a retrospective study of 350 ART-naïve adult patients attending the King Edward VIII HIV clinic, Durban, South Africa. Data were collected at baseline (pre-ART) and at six, 12, 18 and 24 months on ART. Renal function was assessed in the 24-month period using the Modification of Diet in Renal Disease equation and was categorised into normal renal function (estimated glomerular filtration rate [eGFR] ≥ 60), moderate renal impairment (eGFR 30–59), severe renal impairment (eGFR 15–29) and kidney failure (eGFR < 15 mL/min/1.73 m2). Generalised linear models for binary data were used to model the probability of renal impairment over the five time periods, controlling for repeated measures within participants over time. Risk ratios and 95% confidence intervals (CI) were reported for each time point versus baseline. Results: The cohort was 64% female, and 99% were Black. The median age was 36 years. At baseline, 10 patients had hypertension (HPT), six had diabetes, 61 were co-infected with tuberculosis (TB) and 157 patients had a high body mass index (BMI) with 25.4% being categorised as overweight and 19.4% as obese. The majority of the patients (59.3%) were normotensive. At baseline, the majority of the patients (90.4%) had normal renal function (95% CI: 86% – 93%), 7.0% (CI: 5% – 10%) had moderate renal impairment, 1.3% (CI: 0% – 3%) had severe renal impairment and 1.3% (CI: 0% – 3%) had renal failure. As BMI increased by one unit, the risk of renal impairment increased by 1.06 (CI: 1.03–1.10) times. The association of HPT with abnormal renal function was found to be insignificant, p > 0.05. The vast majority of patients were initiated on tenofovir disoproxil fumarate (TDF) (90.6%), in combination with lamivudine (3TC) (100%) and either efavirenz (EFV) (56.6%) or nevirapine (NVP) (43.4%). Conclusion: This study reports a low prevalence of baseline renal impairment in HIV-infected ART-naïve outpatients. An improvement in renal function after the commencement of ART has been demonstrated in this population. However, the long-term outcomes of patients with HIV-related renal disease are not known.